Neuroinflammation in multiple sclerosis: Evidence for autoimmune dysregulation, not simple autoimmune reaction

被引:41
作者
Grigoriadis, N
Grigoriadis, S
Polyzoidou, E
Milonas, I
Karussis, D
机构
[1] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurol, Lab Expt Neurol & Neuroimmunol, Thessaloniki 54636, Greece
[2] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurosurg, Thessaloniki 54636, Greece
[3] Hadassah Univ Hosp, Lab Neuroimmunol, Dept Neurol, IL-91120 Jerusalem, Israel
[4] Hadassah Univ Hosp, Lab Neuroimmunol, Agnes Ginges Ctr Neurogenet, IL-91120 Jerusalem, Israel
关键词
multiple sclerosis; inflammation; regulatory cells;
D O I
10.1016/j.clineuro.2005.11.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Both inflammatory and neurodegenerative components may contribute to the clinical profile of multiple sclerosis (MS) leading to irreversible deficits when they exceed the threshold of compensation. The mechanisms leading to tissue injury in MS are complex. Inflammation appears to be caused by overactive pro-inflammatory T-helper I cells, initiating an inflammatory cascade with several cellular and molecular immune components participating in the pathogenetic mechanism. Current treatments are most effective in the inflammatory phase of the disease since they may interfere with various stages of the immune cascade. Recent evidence has emerged that inflammation may not only be destructive, but may also play a part in tissue repair. This has opened up a new aspect of our knowledge of the role of the inflammatory process in MS. Data regarding the role of regulatory cells in particular, imply that specific immunomodulatory strategies that support the function of these particular cellular subpopulations may participate in the downregulation of autoimmune responses in MS. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:241 / 244
页数:4
相关论文
共 40 条
[11]   Interferon β treatment in relapsing-remitting multiple sclerosis.: A review [J].
Grigoriadis, N .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2002, 104 (03) :251-258
[12]   Multiple sclerosis [J].
Hafler, DA .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (06) :788-794
[13]   Elevated serum levels of IFN-γ, IL-4 and TNF-α/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage [J].
Hohnoki, K ;
Inoue, A ;
Koh, CS .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 87 (1-2) :27-32
[14]   Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3 [J].
Hong, J ;
Li, NL ;
Zhang, XJ ;
Zheng, B ;
Zhang, JWZ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (18) :6449-6454
[15]   Control of regulatory T cell development by the transcription factor Foxp3 [J].
Hori, S ;
Nomura, T ;
Sakaguchi, S .
SCIENCE, 2003, 299 (5609) :1057-1061
[16]   Decreased FOXP3 levels in multiple sclerosis patients [J].
Huan, J ;
Culbertson, N ;
Spencer, L ;
Bartholomew, R ;
Burrows, GG ;
Chou, YK ;
Bourdette, D ;
Ziegler, SF ;
Offner, H ;
Vandenbark, AA .
JOURNAL OF NEUROSCIENCE RESEARCH, 2005, 81 (01) :45-52
[17]   CD4 T cell activation and disease activity at onset of multiple sclerosis [J].
Jensen, J ;
Langkilde, AR ;
Fenst, C ;
Nicolaisen, MS ;
Roed, HG ;
Christiansen, M ;
Sellebjerg, F .
JOURNAL OF NEUROIMMUNOLOGY, 2004, 149 (1-2) :202-209
[18]   An integrated view of suppressor T cell subsets in immunoregulation [J].
Jiang, H ;
Chess, L .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (09) :1198-1208
[19]   Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood [J].
Jonuleit, H ;
Schmitt, E ;
Stassen, M ;
Tuettenberg, A ;
Knop, J ;
Enk, AH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (11) :1285-1294
[20]   Role of ICAM-1 and P-selectin expression in the development and effector function of CD4+CD25+ regulatory T cells [J].
Kohm, AP ;
Miller, SD .
JOURNAL OF AUTOIMMUNITY, 2003, 21 (03) :261-271